Torrent Pharmaceuticals Limited has reported strong financial results for the quarter and year ended March 31, 2026. The company achieved a 42% year-on-year revenue growth in Q4 to ₹4,197 crore, driven by the integration of JB Pharma. The Board has recommended a final dividend of ₹9 per equity share, and announced an enabling approval for raising up to ₹5,000 crore through qualified institutional placement to support future growth strategies.
Annual Financial Performance
For the financial year ended March 31, 2026, Torrent Pharmaceuticals demonstrated significant growth with consolidated revenues reaching ₹13,980 crore, compared to ₹11,516 crore in the previous year. The consolidated profit after tax for FY26 stood at ₹2,138 crore, up from ₹1,911 crore in FY25. The fourth quarter was particularly impactful, with revenue climbing to ₹4,197 crore, representing a 42% YoY increase, while the operating EBITDA margin was sustained at 32.3%.
Strategic Acquisition and Integration
A major highlight of the fiscal year was the acquisition of a controlling stake in JB Chemicals & Pharmaceuticals Limited (JB Pharma), which became effective on January 21, 2026. This strategic move has expanded the company’s footprint and therapeutic presence. The company has already initiated the integration process, and an amalgamation scheme has been filed with the National Company Law Tribunal to further consolidate operations.
Dividend and Future Funding
In appreciation of the shareholders’ support, the Board of Directors has recommended a final dividend of ₹9 per equity share (180% of face value). Looking ahead, the company is seeking enabling approvals from shareholders at the upcoming Annual General Meeting to raise funds through the issuance of equity shares or convertible instruments up to an amount not exceeding ₹5,000 crore, ensuring the financial flexibility needed to pursue further organic and inorganic growth opportunities.
Global Market Highlights
The company continues to perform strongly across key international markets. The India business saw revenue rise by 43% during the quarter. In Brazil, revenue grew by 30%, and the company has 58 products currently under regulatory review. Meanwhile, the United States business posted a 31% revenue increase, supported by the strong performance of new product launches in the base business.
Source: BSE
